Orange Book product · Generic (ANDA)
SUMATRIPTAN SUCCINATE
SUMATRIPTAN SUCCINATE
At a glance
Jul 13, 2021
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jul 13, 2021
5 yr ago
Today
Pharmaceutical detail
Active ingredient
SUMATRIPTAN SUCCINATE
Strength
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)
Dosage form
INJECTABLE
Route
SUBCUTANEOUS
TE code
AP
Application
ANDA 213998
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of SUMATRIPTAN SUCCINATE
- 2016ZEMBRACE SYMTOUCHBrand (NDA)
NDA 208223 · TONIX MEDS
- 2016ONZETRA XSAILBrand (NDA)
NDA 206099 · CURRAX
- 2013SUMAVEL DOSEPROBrand (NDA)
NDA 022239 · ENDO OPERATIONS
- 2013ZECUITYBrand (NDA)
NDA 202278 · TEVA BRANDED PHARM
- 2010ALSUMABrand (NDA)
NDA 022377 · MERIDIAN MEDCL
- 1995IMITREXBrand (NDA)
NDA 020132 · GLAXOSMITHKLINE
- 1992IMITREXBrand (NDA)
NDA 020080 · GLAXOSMITHKLINE
- 2025SUMATRIPTAN SUCCINATEGeneric (ANDA)
ANDA 213518 · ALEMBIC
- 2025SUMATRIPTAN SUCCINATEGeneric (ANDA)
ANDA 206019 · IPCA LABS LTD
- 2024SUMATRIPTAN SUCCINATEGeneric (ANDA)
ANDA 219036 · VKT PHARMA
- 2024SUMATRIPTAN SUCCINATEGeneric (ANDA)
ANDA 215651 · ONESOURCE SPECIALTY
- 2023SUMATRIPTAN SUCCINATEGeneric (ANDA)
ANDA 207101 · BAXTER HLTHCARE CORP
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
